Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Vumerity

    - PMLiVE

    Eisai submits new drug application for subcutaneous Leqembi in Japan

    LEQEMBI is a treatment for early Alzheimer’s disease

    - PMLiVE

    Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

    The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

    - PMLiVE

    Roche’s Lunsumio receives positive CHMP opinion for follicular lymphoma

    The recommendation for the subcutaneous formulation follows encouraging trial data

    - PMLiVE

    Biogen expands portfolio in deal with Alcyone Therapeutics

    The agreement gives Biogen full rights to a potential therapy for patients with neurological disorders

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s drug Leqembi shows continued benefit over four years

    An estimated 13 million people in the US will be living with Alzheimer’s disease by 2050

    EU flag

    CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication

    Non-small cell lung cancer accounts for up to 90% of all lung cancer cases

    Biogen Idec building

    Biogen’s Qalsody granted MHRA approval to treat rare form of motor neurone disease

    Mutations in the SOD1 gene are responsible for approximately 2% of all cases of the disease

    - PMLiVE

    Eli Lilly’s Alzheimer’s disease drug donanemab recommended by CHMP

    Up to 6.9 million people in Europe are affected by the neurodegenerative disorder

    - PMLiVE

    Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP

    Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1

    Biogen Idec building

    Biogen to boost US manufacturing footprint with $2bn North Carolina investment

    The commitment is aimed at advancing the company's late-stage clinical pipeline

    Biogen Idec building

    Biogen initiates phase 3 study of felzartamab in kidney disease patients

    Approximately 36,000 people in the US are affected by primary membranous nephropathy

    EU flag

    CHMP recommends tablet formulation of BeOne’s targeted cancer drug Brukinsa

    The new formulation would allow blood cancer patients to halve their daily pill intake

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links